# Sarepta Therapeutics

Type: Company (SRPT)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/sarepta-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/sarepta-therapeutics

## Timeline

- **2026-03-25**: Options Surge — Traders purchase large volume of call options following clinical data reports.
- **2026-03-25**: Clinical Data Release — Early data for RNA therapies in FSHD and DM1 shows promise.
- **2026-03-20**: Regulatory Strategy — Sarepta announces plan to seek full FDA approval for exon-skipping drugs.
- **2026-03-13**: Analyst Revisions — Multiple brokerages raise price targets for SRPT stock.
- **2026-02-25**: SEC Filing — Company files 8-K regarding changes in director and officer elections.

## Recent coverage (1 stories)

### Sarepta Therapeutics Sees Surge in Call Options Following Rare Disease Data
2026-03-25 19:55:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bullish options activity for Sarepta Therapeutics (SRPT) spiked on March 25, 2026, as the market reacted to promising early data for its RNA-based rare disease pipeline. The increased trading volume coincides with the company’s strategic push for full FDA approval of its core Duchenne muscular dystrophy portfolio.
Full story: https://getbiobrief.com/story/sarepta-therapeutics-options-surge-rare-disease-data

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.